OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE), multi-modality specialty pharma pure-play CDMO, and Xbrane Biopharma AB (Nasdaq ticker XBRANE), a Sweden-headquartered biotechnology company, today announced a strategic partnership focused on the commercial manufacturing of Xbrane’s biosimilar portfolio. Xbrane has a portfolio of biosimilar candidates targeting
OneSource Specialty Pharma Limited today announced the appointment of three new non-executive independent directors to its Board — Dr. Claudio Albrecht, Ms. Debarati Sen and Mr. Vijay Karwal—effective February 27, 2025. The directors bring decades of leadership experience and expertise in Pharma, Business Strategy, Transformation,
OneSource Specialty Pharma, a newly formed CDMO, is formed from the merger of three CDMO businesses within the Strides Group, which boasts a 30-year track-record of excellence in manufacturing and quality. The company is launching its new brand identity with a strong emphasis on customer
Revolutionary technology will further boost OneSource’s scientific services offeringsOneSource Specialty Pharma Limited, associate company of Strides and India’s first specialty pharma pure-play CDMO (Contract Development and Manufacturing Organization) has entered into a strategic licensing agreement with Bhami’s Research Laboratory (BRL). This partnership will provide OneSource
